| Source: |
| Type: |
| Cell Viability |
| 1330- | EMD, | Aloe emodin-induced apoptosis in t-HSC/Cl-6 cells involves a mitochondria-mediated pathway |
| - | in-vitro, | NA, | NA |
| 6815- | EMD, | NMR-based Metabolomic Techniques Identify the Toxicity of Emodin in HepG2 Cells |
| - | in-vitro, | Liver, | HepG2 |
| 6819- | EMD, | Recent advances in the therapeutic potential of emodin for human health |
| - | Review, | Nor, | NA |
| 5223- | EMD, | Emodin inhibits colon cancer by altering BCL-2 family proteins and cell survival pathways |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | Nor, | CCD841 |
| 3460- | EP, | Picosecond pulsed electric fields induce apoptosis in HeLa cells via the endoplasmic reticulum stress and caspase-dependent signaling pathways |
| - | in-vitro, | Cerv, | HeLa |
| 6796- | EPA, | Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Pca, | PANC1 |
| 6793- | EPA, | Contribution of Pyk2 pathway and reactive oxygen species (ROS) to the anti-cancer effects of eicosapentaenoic acid (EPA) in PC3 prostate cancer cells |
| - | in-vitro, | Pca, | PC3 |
| 6797- | EPA, | Effects of cellular redox balance on induction of apoptosis by eicosapentaenoic acid in HT29 colorectal adenocarcinoma cells and rat colon in vivo |
| - | in-vivo, | Colon, | HT29 |
| 975- | Est, | Estrogen inhibits autophagy and promotes growth of endometrial cancer by promoting glutamine metabolism |
| - | vitro+vivo, | UEC, | NA |
| 6578- | EU, | Eurycomanol and eurycomanone as potent inducers for cell-cycle arrest and apoptosis in small and large human lung cancer cell lines |
| - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | A549 |
| 6579- | EU, | Eurycomanone and Eurycomanol from Eurycoma longifolia Jack as Regulators of Signaling Pathways Involved in Proliferation, Cell Death and Inflammation |
| - | in-vitro, | AML, | K562 |
| 6583- | EU, | Inactivation of AKT/NF-κB signaling by eurycomalactone decreases human NSCLC cell viability and improves the chemosensitivity to cisplatin |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | Calu-1 |
| 6584- | EU, | Eurycoma longifolia: an overview on the pharmacological properties for the treatment of common cancer |
| - | Review, | Var, | NA |
| 6390- | Eug, | Molecular mechanisms of eugenol as an antitumour bioactive compound: A comprehensive review |
| - | Review, | Var, | NA |
| 6381- | Eug, | Biological Properties and Prospects for the Application of Eugenol—A Review |
| - | Review, | Var, | NA |
| 6385- | Eug, | Anticancer potential of eugenol in hepatocellular carcinoma through modulation of oxidative stress, inflammation, apoptosis, and proliferation mechanisms |
| - | in-vivo, | HCC, | HepG2 |
| 6338- | Eug, | Tumor suppressive roles of eugenol in human lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 6340- | Eug, | Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MDA-MB-231 |
| 6341- | Eug, | A Metabolomic Investigation of Eugenol on Colorectal Cancer Cell Line HT-29 by Modifying the Expression of APC, p53, and KRAS Genes |
| - | NA, | Colon, | HT29 |
| 6845- | EVO, | Evodiamine, a Novel NOTCH3 Methylation Stimulator, Significantly Suppresses Lung Carcinogenesis in Vitro and in Vivo |
| - | vitro+vivo, | NSCLC, | A549 | - | in-vitro, | Lung, | H1299 |
| 6840- | EVO, | Evodiamine Induces G2/M Arrest and Apoptosis via Mitochondrial and Endoplasmic Reticulum Pathways in H446 and H1688 Human Small-Cell Lung Cancer Cells |
| - | in-vitro, | Lung, | H446 | - | in-vitro, | Lung, | H1688 |
| 6839- | EVO, | Activation of JNK Contributes to Evodiamine-Induced Apoptosis and G2/M Arrest in Human Colorectal Carcinoma Cells: A Structure-Activity Study of Evodiamine |
| - | in-vitro, | CRC, | COLO205 | - | in-vitro, | Colon, | HT29 |
| 1112- | FA, | Ferulic acid exerts antitumor activity and inhibits metastasis in breast cancer cells by regulating epithelial to mesenchymal transition |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | BC, | NA |
| 6857- | FBZ, | Fenbendazole induces pyroptosis in breast cancer cells through HK2/caspase-3/GSDME signaling pathway |
| - | vitro+vivo, | BC, | NA |
| 6427- | FEO, | Foeniculum vulgare seed extract exerts anti-cancer effects on hepatocellular carcinoma |
| - | vitro+vivo, | HCC, | NA |
| 6909- | FIS, | Modulation of PI3K/ AKT/ mTOR and apoptosis pathway in colon cancer cells by the plant flavonoid fisetin |
| - | in-vitro, | Colon, | Caco-2 |
| 6897- | FIS, | Fisetin: A Dietary Antioxidant for Health Promotion |
| - | Review, | Nor, | NA |
| 6899- | FIS, | Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | 22Rv1 |
| 2851- | FIS, | Apoptosis induction in breast cancer cell lines by the dietary flavonoid fisetin |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | SkBr3 | - | in-vitro, | Nor, | NA |
| 2847- | FIS, | Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells |
| - | in-vitro, | CCA, | NA |
| 2856- | FIS, | N -acetyl- L -cysteine enhances fisetin-induced cytotoxicity via induction of ROS-independent apoptosis in human colonic cancer cells |
| - | in-vitro, | Colon, | COLO205 |
| 2844- | FIS, | Fisetin, a dietary flavonoid induces apoptosis via modulating the MAPK and PI3K/Akt signalling pathways in human osteosarcoma (U-2 OS) cells |
| - | in-vitro, | OS, | U2OS |
| 2841- | FIS, | Fisetin, an Anti-Inflammatory Agent, Overcomes Radioresistance by Activating the PERK-ATF4-CHOP Axis in Liver Cancer |
| - | in-vitro, | Nor, | RAW264.7 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | Hep3B | - | in-vitro, | Liver, | HUH7 |
| 2843- | FIS, | Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential |
| - | Review, | Var, | NA |
| 6987- | Form, | Formononetin exhibits anticancer activity in gastric carcinoma cell and regulating miR-542-5p |
| - | vitro+vivo, | GC, | SGC-7901 | - | in-vitro, | BC, | MGC803 |
| 6970- | Form, | Formononetin, an isoflavone from Astragalus membranaceus inhibits proliferation and metastasis of ovarian cancer cells |
| - | in-vitro, | Ovarian, | NA |
| 6965- | Form, | Formononetin inhibits colon carcinoma cell growth and invasion by microRNA‑149‑mediated EphB3 downregulation and inhibition of PI3K/AKT and STAT3 signaling pathways |
| - | in-vitro, | CRC, | HCT116 |
| 6966- | Form, | Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model |
| - | NA, | MM, | NA |
| 6969- | Form, | Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer |
| - | vitro+vivo, | NSCLC, | HCC827 | - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | H1299 |
| 7014- | Fuc, | 5-FU, | Low-Molecular-Weight Fucoidan as Complementary Therapy of Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Colon, | Caco-2 |
| 7020- | Fuc, | Systematic synthesis of low-molecular weight fucoidan derivatives and their effect on cancer cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | WI38 |
| 1114- | Fuc, | The Potential Effect of Fucoidan on Inhibiting Epithelial-to-Mesenchymal Transition, Proliferation, and Increase in Apoptosis for Endometriosis Treatment: In Vivo and In Vitro Study |
| - | vitro+vivo, | NA, | NA |
| - | in-vitro, | Oral, | NA |
| 4024- | FulvicA, | ANTI-CARCINOGENIC ACTIVITY OF SHILAJIT REGARDING TO APOPTOSIS ASSAY IN CANCER CELLS: A SYSTEMATIC REVIEW OF IN-VITRO STUDIES |
| - | Review, | Var, | NA |
| 4025- | FulvicA, | Mumio (Shilajit) as a potential chemotherapeutic for the urinary bladder cancer treatment |
| - | in-vitro, | Bladder, | T24/HTB-9 | - | Review, | AD, | NA |
| 4027- | FulvicA, | Mummy Induces Apoptosis Through Inhibiting of Epithelial-Mesenchymal Transition (EMT) in Human Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF10 |
| 1091- | GA, | Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | HTB-35 |
| 1086- | GA, | Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation |
| - | in-vitro, | AML, | K562 |
| 1065- | GA, | Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression |
| - | vitro+vivo, | Pca, | NA |
| 7049- | GA, | Pharmacological effects of gallic acid in health and diseases: A mechanistic review |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:897 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid